Fixing the Subscription Trap
The FTC’s Negative Option Rule do-over – and what’s at stake.
Bubak et al v. GOLO, LLC
21-cv-492, E.D. Cal.
(March 2021)
GOLO’s Release Supplement
Implying that the supplement mitigates and prevents diabetes, heart disease, and Alzheimer’s disease by claiming that it is “the Natural Solution to Insulin Resistance”
Misleadingly marketing the supplement as “Clinically Proven” when the company relies on pilot studies that it paid for and that have not been peer reviewed or published in legitimate scientific publications
Pending
The FTC’s Negative Option Rule do-over – and what’s at stake.
Be wary of questionable and deceptive claims in origin stories.
Mounting lawsuits accuse Meta of breaking privacy promises.
Breaking down the fine print of this March Madness commercial.
Advertised $19.99 price deserves an official review.